

**Reference:** FOI.ICB-2526/195

**Subject:** Joint Working Arrangements with Pharmaceutical Companies

*I can confirm that the ICB does hold the information requested; please see responses below:*

QUESTION	RESPONSE
<p>I am writing to make a formal request for information under the provisions of the Freedom of Information Act 2000 regarding collaborative working and joint working arrangements entered into by your organisation and companies in the pharmaceutical industry.</p> <p>For clarity, I'm talking about formal arrangements between an NHS organisation and one or more pharmaceutical companies, governed by the Department of Health and Social Care's definition: "Situations where, for the benefit of patients, one or more pharmaceutical companies, the NHS and others (e.g. Patient Groups) pool skills, experience and/or resources for the joint development and implementation of patient-centred projects and share a commitment to successful delivery."</p> <p>Transparency is a must for these projects, according to both the government and the Association of British Pharmaceutical Industry.</p> <p>ABPI oversees the implementation of its code of practice, which contains specific instructions for industry when participating in joint working projects. It says: "All Joint Working projects must be underpinned by a formal Joint Working Agreement, an executive summary of which must be made publicly available before the project begins."</p>	<p>I would therefore like to request the following records from you:</p> <ul style="list-style-type: none"> <li>A copy of the executive summary of each joint working agreement your ICB entered into with a pharmaceutical industry company from 1 April 2019 to 31 August 2025. Please include any records that were held by the predecessor organisations, the clinical commissioning groups, that are now held by your ICB.</li> </ul>
	<ul style="list-style-type: none"> <li>Please refer to the published document as follows for the Exec summary for IQVIA:  <a href="https://assets.ctfassets.net/kwv2olrxu6pq/4h0keqjivq1qVkiwaHrhoT/813269ddf192a4afa28611e6a8cda1c8/UK_AD_CWA_EXEC_SUMMARY_BNSSG_ICB_JAN_25_PP-AD-GB-0252.pdf">https://assets.ctfassets.net/kwv2olrxu6pq/4h0keqjivq1qVkiwaHrhoT/813269ddf192a4afa28611e6a8cda1c8/UK_AD_CWA_EXEC_SUMMARY_BNSSG_ICB_JAN_25_PP-AD-GB-0252.pdf</a> </li> </ul>

- |   |  |
|---|--|
| <ul style="list-style-type: none"><li>• A copy of the ICB's policy on joint working with the pharmaceutical industry.</li></ul> | <ul style="list-style-type: none"><li>• The ICB policy can be found here: <a href="#">Policy for the Sponsorship of Activities by and Joint Working with the Industry - BNSSG Healthier Together</a></li></ul> |
|---|--|

***The information provided in this response is accurate as of 3 November 2025 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.***